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The phase II to III transition in the drug development
process is associated with the highest risk compared to
transition rates between other phases [1]. With increas-
ing pressure to improve efficiency in this process it is
essential that phase II trials are designed based on
informed decisions, and to provide reliable results.
With over 120 different phase II trial designs available
[2], identifying which designs are appropriate can be dif-
ficult and is based on a number of elements. Randomi-
sation, endpoint selection, and statistical design all
contribute to the decision as to which trial design to
use. Additionally, in an environment of ever-changing
treatments and newly developed biomarkers, it is vital
that the way in which treatments may work is incorpo-
rated into the decision making process. As a solution to
identifying designs, a structured thought process, gui-
dance manual and library of phase II trial designs has
been developed [2]. This considers key elements asso-
ciated with identifying a phase II trial design, and is
intended to facilitate interaction between the clinician
and statistician, as well as providing a structured and
systematic approach to identifying appropriate trial
designs.
Challenges remain, however, in choosing between a
number of designs identified that fit trial-specific design
criteria. Researchers may consider practical elements of
conducting a trial, or previous experience, to determine
which design to use. However further consideration to
the performance of different designs may be necessary.
Simulation provides an ideal opportunity to evaluate
this under differing trial scenarios, and is often used in
the design of phase I trials.
A no v e r v i e wo ft h er o l eo fp h a s eI It r i a l si nt h ed r u g
development pathway will be presented, highlighting
current issues and solutions to identifying appropriate
trial designs, including a worked example. Further dis-
cussion will include the challenges in choosing between
designs, with an example of the use of simulation to
evaluate trial design presented.
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